Antimicrobial activity of lipoprotein particles containing apolipoprotein Al.
Human plasma in vitro inhibits the growth of coagulase negative staphylococci, S. epidermidis, which may be pathogenic in the immunocompromised host. To determine the antimicrobial components, serum was fractionated by column chromatography, which revealed that elution areas where lipoproteins can be yielded had high antimicrobial activity against S. epidermidis. Therefore, lipoprotein fractions, including very low density lipoprotein (VLDL), low density lipoprotein (LDL) and high density lipoprotein (HDL), were separated by ultracentrifugation and incubated with S. epidermidis. All 3 lipoprotein fractions suppressed bacterial growth within the first 3 h but VLDL enhanced bacterial growth after 9 h of incubation compared with the control. HDL, however, inhibited bacterial growth throughout 21 h of incubation. To confirm these results, serum from healthy volunteers was separated by ion exchange column chromatography and again by HPLC to purify the antimicrobial fraction. In the protein analysis with gradient polyacrylamide-SDS gel, apolipoprotein Al (apo Al), which is a major apolipoprotein of HDL, was detected in the antimicrobial fraction. Therefore, this fraction was loaded onto an immunoaffinity column coupled with the anti-apo Al monoclonal antibody (Mab). Unbound fraction had no antimicrobial activity, but anti-S. epidermidis activity was recovered from the bound fraction which consisted mainly of apo Al, All and apo C in protein composition. These results indicated that the antimicrobial activity was associated with the apo Al-containing lipoprotein particles (HDL). This property of HDL may directly affect bacterial growth and promote the self-defense mechanisms of normal and immunocompromised individuals.
Tada
N
N
Department of Internal Medicine, Aoto Hospital, Jikei University School of Medicine, Japan.
Sakamoto
T
T
Kagami
A
A
Mochizuki
K
K
Kurosaka
K
K
D000900:Anti-Bacterial Agents / Q000097:blood / Q000302:isolation & purification / Q000494:pharmacology*; D016632:Apolipoprotein A-I / Q000494:pharmacology*; D001790:Blood Physiological Phenomena; D006801:Humans; D008075:Lipoproteins, HDL / Q000494:pharmacology*; D013212:Staphylococcus epidermidis / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D016632:Apolipoprotein A-I; D008075:Lipoproteins, HDL